SGLT2 inhibitors linked to reduced dementia risk in adults with traumatic brain injury and type 2 diabetes

A new study suggests that starting SGLT2 inhibitors for adults with type 2 diabetes and a history of traumatic brain injury may lower the risk of developing dementia, marking a potential shift in neuroprotective strategies in complex diabetes care.

In adults with type 2 diabetes and a history of traumatic brain injury, starting a sodium-glucose cotransporter 2 inhibitor was linked to a lower risk of developing dementia than beginning treatment with a dipeptidyl peptidase-4 inhibitor, according to a retrospective cohort study using the TriNetX Research Network. The analysis, published in a peer-reviewed journal, adds to a growing body of evidence that has already suggested possible cognitive advantages for SGLT2 drugs in broader diabetes populations.

The researchers identified 3,877 patients in each treatment group after propensity score matching and used a 1-year landmark period to reduce the chance that early cognitive decline influenced drug choice or outcome measurement. Over follow-up of up to 10 years, dementia occurred less often in the SGLT2 group, with the primary analysis showing a hazard ratio of 0.71. The study also found lower rates of vascular dementia and all-cause mortality, while Alzheimer’s disease was not significantly different between the groups.

That pattern is broadly in line with earlier work. A population-based cohort study indexed by PubMed in 2023 reported lower dementia risk with SGLT2 inhibitors than with DPP-4 inhibitors in older adults with type 2 diabetes, while a later analysis published in 2024 found reduced dementia risk with SGLT2 drugs versus sulfonylureas, though with subgroup variation. A recent systematic review and meta-analysis also reported lower risks of all-cause dementia, Alzheimer’s disease and vascular dementia with SGLT2 inhibitors compared with DPP-4 inhibitors.

Still, the new study is narrower and clinically more specific than much of the earlier literature because it focuses on people already at elevated neurological risk after brain injury. The authors said the association remained broadly consistent in sensitivity analyses, including a restriction to empagliflozin users and an analysis limited to coded non-concussion intracranial injuries. They cautioned, however, that the work was observational and could not prove that SGLT2 inhibitors prevent dementia or alter post-traumatic neurodegeneration.

The findings also fit with the broader rationale for choosing SGLT2 therapy in complex diabetes care. These drugs have established benefits for cardiovascular and kidney outcomes and may influence inflammation, oxidative stress and vascular function, all of which are relevant to long-term brain health. But the study’s authors stressed that diagnostic coding, survivor bias, missing clinical detail on injury severity and unmeasured confounding all limit how far the results can be taken.